Cabaletta Bio, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Cabaletta Bio is a clinical-stage biotechnology company developing engineered CAAR T-cell therapies for B-cell-mediated autoimmune diseases. The filing covers the quarter and six months ended June 30, 2022; financial statements are unaudited and presented in thousands except per-share and share data.
The lead program, DSG3-CAART, was being evaluated in the Phase 1 DesCAARTes trial for mucosal pemphigus vulgaris. MuSK-CAART received FDA fast track designation and an effective IND in early 2022, with the MusCAARTes Phase 1 trial planned for the second half of 2022. The company had not generated product revenue and had no approved products.
Key Financial Metrics
| Metric | Three months ended June 30, 2022 | Three months ended June 30, 2021 | Six months ended June 30, 2022 | Six months ended June 30, 2021 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $9.5 million | $7.9 million | $18.7 million | $14.4 million |
| General and administrative expense | $3.5 million | $3.3 million | $7.4 million | $6.5 million |
| Total operating expenses | $13.1 million | $11.1 million | $26.1 million | $20.9 million |
| Net loss | $12.9 million | $11.1 million | $25.9 million | $20.8 million |
| Net loss per share, basic and diluted | $0.45 loss | $0.45 loss | $0.89 loss | $0.86 loss |
| Net cash used in operating activities | Not separately provided | Not separately provided | $24.3 million | $15.3 million |
There were no meaningful operating margins because the company had no revenue and reported operating losses. Interest income was $0.2 million for the first six months of 2022, compared with less than $0.1 million in the prior-year period.
- Cash and cash equivalents at June 30, 2022: $47.2 million.
- Short-term investments: $49.6 million, consisting of U.S. government securities.
- Total cash, cash equivalents and investments: $96.8 million.
- Total assets: $102.0 million; total current liabilities: $6.5 million.
- Accumulated deficit: $138.4 million.
- The filing does not disclose outstanding debt or a credit facility; management stated that the company had no committed sources of capital.
- Common shares outstanding as of August 5, 2022: 29.0 million.
Cash Flow, Liquidity and Capital Resources
Operating cash use increased to $24.3 million in the first six months of 2022 from $15.3 million in the comparable 2021 period. Investing cash use was $50.8 million, primarily reflecting $49.8 million of purchases of investments and $1.0 million of property and equipment purchases. Financing activities provided only $0.1 million from option exercises and the employee stock purchase plan; no shares were sold under the $75.0 million ATM program in 2022.
Management stated that cash and cash equivalents at June 30, 2022 were expected to fund projected operations for at least 12 months after filing. Separately, based on the current operating plan and including investments, management expected available resources to fund operations through the first quarter of 2024. These estimates depend on assumptions that may prove incorrect, and additional capital will be required to advance clinical development and fund operations.
Material Changes Versus the Prior Comparable Period
- Six-month research and development expense increased $4.3 million, or approximately 30%, primarily due to higher personnel costs, clinical trial costs, manufacturing activities and sponsored research.
- Six-month general and administrative expense increased $0.9 million, or approximately 14%, largely due to increased personnel costs, partly offset by lower directors’ and officers’ insurance costs.
- Total operating expenses increased $5.2 million, or approximately 25%, and six-month net loss increased $5.0 million, or approximately 24%.
- Operating cash burn increased by approximately $9.1 million.
- Cash and cash equivalents declined from $122.2 million at December 31, 2021 to $47.2 million at June 30, 2022, while $49.6 million was invested in short-term government securities.
- Stock-based compensation increased to $3.6 million from $2.7 million for the first six months.
Guidance, Outlook, Risks and Unusual Items
- Management expected research and development and general and administrative expenses to continue increasing as clinical programs, manufacturing activities and infrastructure expand.
- The DesCAARTes trial was progressing through dose escalation. Prior disclosed cohorts had no dose-limiting toxicities, serious adverse events or clinically relevant adverse events within the reported observation periods, but early low-dose cohorts showed no clear evidence of biologic activity. These results were preliminary and not predictive of later cohorts.
- The company planned to evaluate additional DSG3-CAART cohorts, including multi-dose and preconditioning approaches. Preconditioning may increase safety risks and complicate interpretation of biologic activity.
- Material execution risks include patient enrollment, clinical safety and efficacy, regulatory approval, manufacturing scalability, technology transfer from Penn, third-party manufacturing capacity, lentiviral-vector supply, intellectual-property protection and the continuing impact of COVID-19.
- The company relies heavily on Penn for research, development and current manufacturing activities and on other third parties for clinical, manufacturing and support services.
- The Penn license agreement could require approximately $21.0 million of aggregate milestone payments if multiple products are successfully developed and launched, plus low-single-digit royalties on product sales. No amounts were due under the license at June 30, 2022.
- Operating lease commitments totaled approximately $9.8 million as of June 30, 2022. The WuXi manufacturing arrangement carried a potential early termination fee of up to $1.5 million; in August 2022, the dedicated suite arrangement was converted to a shared suite arrangement with a lower monthly fee.
- A purported stockholder filed a securities class-action complaint in February 2022 concerning statements and omissions related to the DesCAARTes trial and DSG3-CAART. The company intended to defend the lawsuit, but the outcome and potential loss could not be estimated; no accrual was recorded.
- Management concluded that disclosure controls were effective at a reasonable assurance level and reported no material change in internal control over financial reporting during the quarter.
Most Important Facts for Investors to Verify
- Whether clinical data from higher-dose and preconditioned DesCAARTes cohorts demonstrate biologic activity, durability and an acceptable safety profile.
- Whether the MusCAARTes trial began on schedule and whether enrollment, manufacturing and regulatory timelines remain achievable.
- The pace of operating cash burn and whether the stated runway through the first quarter of 2024 remains valid after clinical, manufacturing and infrastructure spending.
- The timing and terms of additional financing, including potential dilution from future equity offerings or use of the remaining ATM capacity.
- Progress and risk in transferring manufacturing from Penn to contract manufacturers, including Oxford Biomedica, WuXi and other suppliers.
- The status, cost exposure and potential effect of the securities class-action litigation.
- Whether the company’s license, intellectual-property and sponsored-research arrangements remain in good standing and support the planned pipeline.